肝病治疗药物市场按治疗类型、分销管道和地区：2023-2030 年市场规模、份额、前景、机会分析

Liver Diseases Therapeutics Market, Therapy Type, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年07月25日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3个工作天内

价格

简介目录

肝臟是人体最大的器官。它的功能是消化食物、储存能量、排除毒素。肝臟疾病有多种类型，包括由甲型、B型、C型肝炎等病毒引起的肝臟疾病，以及因过量摄取药物、毒物和酒精引起的肝臟疾病。例子包括脂肪肝和肝硬化。活癌也是一种数量不断增加的疾病。还有几种影响肝臟的遗传性疾病，例如血色素沉着症和威尔森氏症。影响肝臟的疾病的常见症状包括腹部或腿部肿胀、容易瘀青、黄疸以及粪便或尿液颜色的变化。影像学检查和肝功能检查可用于检查肝损伤和诊断肝病。肝病的治疗包括抗排斥药物/免疫抑制剂、化疗药物、标靶治疗、疫苗、抗病毒药物、免疫球蛋白和皮质类固醇。

市场动态

肝病市场的发展、新疗法的研发以及肝病治疗的监管批准正在推动全球肝病药物市场的成长。例如，2022年5月26日，美国製药公司Pfizer公司宣布，美国食品药物管理局已批准Pfizer公司的在研药物联合疗法作为与肝纤维化相关的非酒精性脂肪性肝炎（NASH）的治疗方法。已被指定轨道。快速通道是一个旨在加速新药和疫苗的开发和审查的过程，旨在治疗和预防严重疾病并解决未满足的医疗需求。合併治疗的两种药物是ervogastat和clesacostat。该决定是基于Pfizer非临床和 2a 期临床试验中该药物积极的安全性和耐受性，以及肝臟脂肪的减少。

本次考试的主要特色

本报告对全球肝病治疗药物市场进行了详细分析，并提出了以2022年为基准年的预测期（2023-2030年）的市场规模和復合年增长率（CAGR）。
它也揭示了各个细分市场的潜在收入机会，并为该市场提供了一系列有吸引力的投资建议。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和批准、市场趋势、区域前景、主要参与者采取的竞争策略等的重要见解。
根据公司亮点、产品组合、主要亮点、绩效和策略等参数对全球肝病治疗药物市场的主要公司进行了分析。
本研究涵盖的主要公司包括Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
此报告的见解使行销人员和公司高层能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
《全球肝病治疗药物市场报告》是针对该产业的各个利害关係人，例如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球肝病治疗药物市场的各种策略矩阵，将有助于利害关係人做出决策。

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
英国
德国
义大利
法国
西班牙
俄罗斯
欧洲其他地区
亚太地区
中国
印度
日本
东协
澳大利亚
韩国
其他亚太地区
中东
海湾合作委员会
以色列
其他中东地区
非洲
北非
中非
南非

第八章竞争态势

Astellas Pharma Inc.
Bristol-Myers Squibb.
Gilead Sciences
Glaxosmithkline Plc
Hoffmann-La Roche Ltd
Merck & Co.
Novartis AG
Sanofi S.A
Pfizer Inc.
Takeda Pharmaceuticals
Valeant Pharmaceuticals
Watson Pharmaceuticals, Inc.
Theratechnologies Inc.
Alnylam Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc.
Dicerna Pharmaceuticals, Inc.
Endo International
Provectus Biopharmaceuticals Inc.
MAX BioPharma, Inc.

第 9 章

调查方法
关于出版商

简介目录

Product Code: CMI3809

Liver is the largest organ of the human body. It helps to digest food, store energy, and remove poisons. There are many kinds of liver diseases like diseases caused by viruses such as hepatitis A, hepatitis B, and hepatitis C. Diseases can also be caused by drugs, poisons, or too much alcohol consumption. Examples include fatty liver disease and cirrhosis. Live cancer is another growing disease. There are several inherited disorders like hemochromatosis and Wilson disease that affect the liver. The common symptoms of diseases affecting the liver include swelling of the abdomen and legs, bruising easily, Jaundice, and change in color of stool and urine. Imaging tests and liver function tests can check liver damage and diagnose liver disease. Treatments given for liver diseases include anti-rejection drugs/immunosuppressants, chemotherapy drugs, targeted therapy, vaccines, anti-viral drugs, immunoglobulins, and corticosteroids.

Market Dynamics

Increasing prevalence of liver diseases, research and development of novel therapeutics, and approvals from regulatory bodies for liver disease treatment are attributed to the growth of the global liver diseases therapeutics market. For instance, on May 26, 2022, Pfizer Inc., U.S. based pharmaceutical company announced U.S. Food and Drug Administration granted fast-track designation to Pfizer's investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address unmet medical needs. The two drugs in combinational therapies are ervogastat and clesacostat. The decision was made based on Pfizer's nonclinical studies and phase 2a clinical study of drugs which showed reduced liver fat with favorable safety and tolerability profile.

Key features of the study:

This report provides an in-depth analysis of the global liver diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global liver diseases therapeutics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc..
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver diseases therapeutics market.

Detailed Segmentation:

Global Liver Diseases Therapeutics Market, Therapy Type:
- Anti-Rejection Drugs/Immunosuppressant
- Chemotherapy Drugs
- Targeted therapy
- Vaccines
- Anti-Viral Drugs
- Immunoglobulin's
- Corticosteroids
Global Liver Diseases Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Liver Diseases Therapeutics Market, By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Company Profiles
- Astellas Pharma Inc.
- Bristol-Myers Squibb
- Gilead Sciences
- Glaxosmithkline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Liver Diseases Therapeutics Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Liver Diseases Therapeutics Market, By Therapy Type, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Anti-Rejection Drugs/Immunosupressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Targeted therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Anti-Viral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)

6. Global Liver Diseases Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)

7. Global Liver Diseases Therapeutics Market, By Region, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Glaxosmithkline Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Takeda Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Valeant Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Watson Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Theratechnologies Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Alnylam Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Protagonist Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Dicerna Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Endo International
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Provectus Biopharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
MAX BioPharma, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies